Researchers from Weill Cornell Medicine and the Massachusetts Institute of Technology have identified a critical link between the loss of the transcription factor GATA6 and the ability of colorectal cancer cells to metastasize to the liver. The findings were published on June 22 in the journal Cell Stem Cell.
Key Findings
The study indicates that GATA6 functions as a regulator of intestinal cell identity. According to the research, the loss of GATA6 triggers a process referred to as lineage plasticity, where colorectal cancer cells transition from an LGR5-positive state to an LGR5-negative state. This shift is associated with the cells adopting characteristics similar to fetal cells, which the authors describe as a more primitive and adaptable state.
- Reduced expression of GATA6 was observed in liver metastases in both mouse models and human patient samples.
- Lower levels of GATA6 were correlated with poorer clinical outcomes.
- In mice, genetic deletion of GATA6 increased the frequency and overall burden of liver metastases.
- The loss of GATA6 did not significantly affect the growth of primary tumors.
- Restoring GATA6 expression in cancer cells was associated with a reduction in their metastatic ability.
"The loss of GATA6 triggers a process referred to as lineage plasticity, where colorectal cancer cells transition from an LGR5-positive state to an LGR5-negative state."
Research Methodology
The research team developed organoids derived from liver metastases. These organoids were then transplanted into the colons of mice. The process was repeated iteratively to select for cells with increased metastatic behavior, allowing the researchers to study the associated cell state transitions.
Implications and Future Research
The study's authors propose that GATA6 expression levels could serve as a biomarker for assessing metastatic risk. Tumors with low GATA6 may be more likely to spread.
Potential therapeutic approaches mentioned in the study include strategies aimed at stabilizing cell identity or preventing the transition to a pro-metastatic state. The authors note that avoiding disruption of normal tissue repair processes remains a challenge for such therapies.
Future studies are expected to focus on identifying vulnerabilities in GATA6-deficient cancer cells and investigating the role of the tumor microenvironment in this process.
Funding
The study was supported by various foundations and the National Institutes of Health (NIH).